KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

Ítems similars

• KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
  per: Pacheco, Jose M.
  Publicat: (2019)
• KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
  per: Cummings, Amy Lauren, et al.
  Publicat: (2019)
• Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
  per: Xu, Zhijie, et al.
  Publicat: (2020)
• KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%
  per: Morgensztern, Daniel
  Publicat: (2019)
• Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
  per: Nishio, Shin, et al.
  Publicat: (2020)